vs

Side-by-side financial comparison of Flux Power Holdings, Inc. (FLUX) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Flux Power Holdings, Inc. is the larger business by last-quarter revenue ($14.1M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). Flux Power Holdings, Inc. runs the higher net margin — 4.3% vs -1398.3%, a 1402.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -16.1%). Flux Power Holdings, Inc. produced more free cash flow last quarter ($-5.3M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -1.2%).

Adrian Flux is a British insurance broker that has its head office at East Winch Hall in King's Lynn, Norfolk. The company has become the country’s largest specialist motor insurance brokers and employs around 1,850 staff.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FLUX vs RNA — Head-to-Head

Bigger by revenue
FLUX
FLUX
1.1× larger
FLUX
$14.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+450.1% gap
RNA
434.0%
-16.1%
FLUX
Higher net margin
FLUX
FLUX
1402.6% more per $
FLUX
4.3%
-1398.3%
RNA
More free cash flow
FLUX
FLUX
$151.6M more FCF
FLUX
$-5.3M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-1.2%
FLUX

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
FLUX
FLUX
RNA
RNA
Revenue
$14.1M
$12.5M
Net Profit
$601.0K
$-174.4M
Gross Margin
34.7%
Operating Margin
5.6%
-1513.5%
Net Margin
4.3%
-1398.3%
Revenue YoY
-16.1%
434.0%
Net Profit YoY
131.8%
-117.0%
EPS (diluted)
$0.03
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLUX
FLUX
RNA
RNA
Q4 25
$14.1M
Q3 25
$13.2M
$12.5M
Q2 25
$16.7M
$3.8M
Q1 25
$16.7M
$1.6M
Q4 24
$16.8M
$3.0M
Q3 24
$16.1M
$2.3M
Q2 24
$13.4M
$2.0M
Q1 24
$14.5M
$3.5M
Net Profit
FLUX
FLUX
RNA
RNA
Q4 25
$601.0K
Q3 25
$-2.6M
$-174.4M
Q2 25
$-1.2M
$-157.3M
Q1 25
$-1.9M
$-115.8M
Q4 24
$-1.9M
$-102.3M
Q3 24
$-1.7M
$-80.4M
Q2 24
$-2.2M
$-70.8M
Q1 24
$-3.0M
$-68.9M
Gross Margin
FLUX
FLUX
RNA
RNA
Q4 25
34.7%
Q3 25
28.6%
Q2 25
34.5%
Q1 25
31.6%
Q4 24
32.5%
Q3 24
32.4%
Q2 24
26.9%
Q1 24
27.8%
Operating Margin
FLUX
FLUX
RNA
RNA
Q4 25
5.6%
Q3 25
-16.5%
-1513.5%
Q2 25
-4.5%
-4448.7%
Q1 25
-9.4%
-8360.9%
Q4 24
-8.8%
-4069.6%
Q3 24
-7.5%
-4200.9%
Q2 24
-13.5%
-4040.4%
Q1 24
-17.8%
-2178.6%
Net Margin
FLUX
FLUX
RNA
RNA
Q4 25
4.3%
Q3 25
-19.4%
-1398.3%
Q2 25
-7.0%
-4089.3%
Q1 25
-11.6%
-7360.0%
Q4 24
-11.2%
-3439.5%
Q3 24
-10.4%
-3441.7%
Q2 24
-16.8%
-3461.8%
Q1 24
-20.8%
-1943.4%
EPS (diluted)
FLUX
FLUX
RNA
RNA
Q4 25
$0.03
Q3 25
$-0.15
$-1.27
Q2 25
$-0.07
$-1.21
Q1 25
$-0.12
$-0.90
Q4 24
$-0.11
$-0.80
Q3 24
$-0.10
$-0.65
Q2 24
$-0.13
$-0.65
Q1 24
$-0.18
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLUX
FLUX
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$7.5M
$1.9B
Total Assets
$30.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLUX
FLUX
RNA
RNA
Q4 25
Q3 25
$1.6M
$350.2M
Q2 25
$1.3M
$243.9M
Q1 25
$505.0K
$254.2M
Q4 24
$883.0K
$219.9M
Q3 24
$559.0K
$370.2M
Q2 24
$643.0K
$575.8M
Q1 24
$1.3M
$471.4M
Stockholders' Equity
FLUX
FLUX
RNA
RNA
Q4 25
$7.5M
Q3 25
$-3.3M
$1.9B
Q2 25
$-5.4M
$1.2B
Q1 25
$4.4M
$1.3B
Q4 24
$-2.7M
$1.4B
Q3 24
$-1.1M
$1.5B
Q2 24
$194.0K
$1.2B
Q1 24
$2.1M
$830.9M
Total Assets
FLUX
FLUX
RNA
RNA
Q4 25
$30.1M
Q3 25
$29.7M
$2.1B
Q2 25
$34.8M
$1.4B
Q1 25
$30.6M
$1.5B
Q4 24
$29.0M
$1.6B
Q3 24
$30.6M
$1.6B
Q2 24
$32.3M
$1.3B
Q1 24
$34.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLUX
FLUX
RNA
RNA
Operating Cash FlowLast quarter
$-5.2M
$-156.2M
Free Cash FlowOCF − Capex
$-5.3M
$-156.9M
FCF MarginFCF / Revenue
-37.4%
-1257.6%
Capex IntensityCapex / Revenue
0.9%
5.7%
Cash ConversionOCF / Net Profit
-8.59×
TTM Free Cash FlowTrailing 4 quarters
$-6.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLUX
FLUX
RNA
RNA
Q4 25
$-5.2M
Q3 25
$889.0K
$-156.2M
Q2 25
$610.0K
$-199.7M
Q1 25
$-1.6M
$-124.8M
Q4 24
$2.8M
$-99.9M
Q3 24
$944.0K
$-65.6M
Q2 24
$-4.8M
$-65.0M
Q1 24
$-229.0K
$-70.4M
Free Cash Flow
FLUX
FLUX
RNA
RNA
Q4 25
$-5.3M
Q3 25
$726.0K
$-156.9M
Q2 25
$-43.0K
$-203.0M
Q1 25
$-1.7M
$-128.6M
Q4 24
$2.7M
$-103.8M
Q3 24
$746.0K
$-67.3M
Q2 24
$-5.7M
$-65.5M
Q1 24
$-479.0K
$-71.3M
FCF Margin
FLUX
FLUX
RNA
RNA
Q4 25
-37.4%
Q3 25
5.5%
-1257.6%
Q2 25
-0.3%
-5277.1%
Q1 25
-10.4%
-8174.3%
Q4 24
16.1%
-3491.0%
Q3 24
4.6%
-2881.8%
Q2 24
-42.2%
-3204.6%
Q1 24
-3.3%
-2012.3%
Capex Intensity
FLUX
FLUX
RNA
RNA
Q4 25
0.9%
Q3 25
1.2%
5.7%
Q2 25
3.9%
86.9%
Q1 25
1.1%
238.6%
Q4 24
0.7%
131.7%
Q3 24
1.2%
72.9%
Q2 24
6.4%
26.0%
Q1 24
1.7%
25.8%
Cash Conversion
FLUX
FLUX
RNA
RNA
Q4 25
-8.59×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons